Please ensure Javascript is enabled for purposes of website accessibility
Cory Renauer

Cory Renauer


Cory is a long-term minded analyst focused on the Healthcare Sector. He genuinely enjoys cutting through the complexity to help everyday investors make better decisions.

Recent articles


September Sell-Off Alert: Buy Vertex Pharmaceuticals on the Dip

Shares of this highly successful biotech stock are trading at an all-time low earnings multiple.


Here's Why Eargo Stock Is Imploding Today

An investigation related to insurance claims isn't going over well with investors.


Why Wall Street Thinks This Biotech Stock Can Triple Your Money

The risks are huge, but so are the potential returns.


Why Dynavax Technologies Stock Is Soaring Today

A COVID-19 vaccine candidate that employs the company's adjuvant technology produced positive clinical trial results.


Why Verrica Pharmaceuticals Stock Is Getting Pummeled Today

The Food and Drug Administration delivered some bad news regarding the company's dermatology candidate.


Here's Why Everyone's Talking About AstraZeneca Right Now

The company's next-generation treatment for breast cancer could become the new standard of care.


Cathie Wood Goes Bargain Shopping: 3 Sinking Stocks She Keeps Buying

The CEO of ARK Invest is averaging down on these compelling life-science stocks.


Why Protagonist Therapeutics Stock Is Tanking Today

The FDA put a clinical hold on one of the biotech's new drug candidates.


Here's Why Innate Pharma Stock Is Rocketing Higher Today

A clinical trial with an experimental lung cancer drug produced some positive results.


3 Top Healthcare Stocks You Can Buy for $100 or Less

It doesn't take a lot of upfront cash to add one of these stocks to your portfolio.


Why Regenxbio Stock Is Way Up Today

American biopharmaceutical giant AbbVie wants access to Regenexbio's gene therapy for macular degeneration.


Here's Why iRhythm Technologies Stock Is Making Big Gains Today

A new CEO with an impressive record is giving investors hope for a rapid turnaround for the heart monitor maker.


3 Stocks That Could Soar 50% or Better, According to Wall Street

All three of these growth stocks are poised to put up big gains once more investors land on the same page as investment bank analysts who follow them.


Here's Why Iveric Bio Stock Is Rocketing Higher Today

Mixed results from Apellis Pharmaceuticals are good news for Iveric Bio's geographic atrophy program.


Here's Why Apellis Pharmaceuticals Is Getting Hammered Today

Conflicting clinical trial results for the company's lead candidate are to blame.


Here's Why Ziopharm Oncology Stock Is Up 18% This Week

Recent insider stock purchases were more than a little encouraging.


Here's Why ProQR Stock Surged on Thursday

A new collaboration deal with Eli Lilly could be worth up to $1.3 billion.

stock-trader-losing-money-investment-growth-value-getty (1)

Here's Why Humanigen Is Getting Hammered Today

An attempt to earn authorization for lenzilumab hit a wall at the FDA.


Cathie Wood Goes Dumpster Diving: 3 Beaten Down Stocks She Just Bought

All of these stocks are more than 40% below their peaks, but at least one important investor thinks they can recover.


3 High-Growth Healthcare Stocks to Buy in September

All three are rapidly expanding into their own corners of America's $4 trillion per year healthcare sector.